Connor, Clark & Lunn Investment Management (CC&L)
LENZ

Connor, Clark & Lunn Investment Management (CC&L)’s LENZ Therapeutics LENZ Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Buy
+37,314
New +$524K ﹤0.01% 1393

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LENZ Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 37,314 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #1393 among its holdings.

145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 37,314 shares of LENZ Therapeutics worth $341K as of Q1 2026.
  • LENZ Therapeutics was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1393 holding.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.